相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long non-coding RNA BANCR promotes proliferation and migration in oral squamous cell carcinoma via MAPK signaling pathway
Chun Yao et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2021)
MEK inhibitor resistance mechanisms and recent developments in combination trials
E. Kun et al.
CANCER TREATMENT REVIEWS (2021)
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers
J. Wu et al.
INVESTIGATIONAL NEW DRUGS (2021)
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Andrew X. Zhu et al.
BRITISH JOURNAL OF CANCER (2021)
Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies
Xiufeng Liu et al.
FUTURE ONCOLOGY (2021)
The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance
Mai-Huong Thi Ngo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
Alessandro Rizzo et al.
IMMUNOTHERAPY (2021)
Exosome in Hepatocellular Carcinoma: an update
Wei Chen et al.
JOURNAL OF CANCER (2021)
The MEK/ERK Network as a Therapeutic Target in Human Cancer
Renee Barbosa et al.
MOLECULAR CANCER RESEARCH (2021)
miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation
Amani Ghousein et al.
LIVER INTERNATIONAL (2020)
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Shannon Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pumping the brakes on RAS - negative regulators and death effectors of RAS
Desmond R. Harrell Stewart et al.
JOURNAL OF CELL SCIENCE (2020)
Expression of c-Met in Primary and Recurrent Hepatocellular Carcinoma
Yoshinari Asaoka et al.
ONCOLOGY (2020)
ERK/MAPK signalling pathway and tumorigenesis
Yan-Jun Guo et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2020)
Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond
Samuel J. Klempner et al.
CANCER DISCOVERY (2020)
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Manali Dimri et al.
CANCERS (2020)
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Ufuk Degirmenci et al.
CELLS (2020)
The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
Haiyu Wang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Understanding MAPK Signaling Pathways in Apoptosis
Jicheng Yue et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
Elizabeth Iannotti Buchbinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Clint A. Stalnecker et al.
SCIENCE SIGNALING (2020)
Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
Emmanuele De Luca et al.
CANCER MANAGEMENT AND RESEARCH (2020)
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors
Xi Yuan et al.
MOLECULAR ONCOLOGY (2020)
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M. Gross et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
K-Ras prenylation as a potential anticancer target
Marcell Baranyi et al.
CANCER AND METASTASIS REVIEWS (2020)
Clinical Challenges of Immune Checkpoint Inhibitors
Maria de Miguel et al.
CANCER CELL (2020)
Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy
Hui Hua et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
ERK signalling: a master regulator of cell behaviour, life and fate
Hugo Lavoie et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Jimin Yuan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
LncRNA LL22NC03-N14H11.1 promoted hepatocellular carcinoma progression through activating MAPK pathway to induce mitochondrial fission
Tingzhuang Yi et al.
CELL DEATH & DISEASE (2020)
Hepatocellular carcinoma: old friends and new tricks
Eunsun Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Clinical Development of BRAF plus MEK Inhibitor Combinations
Vivek Subbiah et al.
TRENDS IN CANCER (2020)
Exosomes: key players in cancer and potential therapeutic strategy
Jie Dai et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors
Sofia S. Pereira et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?
Giandomenico Roviello et al.
INVESTIGATIONAL NEW DRUGS (2019)
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
Pietro Paolo Vitiello et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Efficacy of MEK inhibition in patients with histiocytic neoplasms
Eli L. Diamond et al.
NATURE (2019)
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
Fernanda Faiao-Flores et al.
CLINICAL CANCER RESEARCH (2019)
Human DNA Virus Exploitation of the MAPK-ERK Cascade
Jeanne K. DuShane et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai et al.
CELLS (2019)
Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link
Chaobo Chen et al.
CELLS (2019)
LBA61A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer
D M Gershenson et al.
ANNALS OF ONCOLOGY (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
Antonio Gnoni et al.
MEDICINA-LITHUANIA (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Exosomes in hepatocellular carcinoma: a new horizon
Rui Chen et al.
CELL COMMUNICATION AND SIGNALING (2019)
Goals and targets for personalized therapy for HCC
Thomas Couri et al.
HEPATOLOGY INTERNATIONAL (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Hepatocellular Carcinoma: Etiology and Current and Future Drugs
Aastha Jindal et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2019)
Insulin-Like Growth Factor (IGF) System in Liver Diseases
Agnieszka Adamek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa et al.
LANCET ONCOLOGY (2018)
Sp1-regulated transcription of RasGRP1 promotes hepatocellular carcinoma (HCC) proliferation
Xinran Zhang et al.
LIVER INTERNATIONAL (2018)
HCC-derived exosomes elicit HCC progression and recurrence by epithelialmesenchymal transition through MAPK/ ERK signalling pathway
Lu Chen et al.
CELL DEATH & DISEASE (2018)
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Feifei Liu et al.
ACTA PHARMACEUTICA SINICA B (2018)
SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
Thomas Strub et al.
NATURE COMMUNICATIONS (2018)
The Role of MicroRNAs in Hepatocellular Carcinoma
Xin Xu et al.
JOURNAL OF CANCER (2018)
miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling
Shuai Xiao et al.
ONCOGENESIS (2018)
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Tatsuya Nagano et al.
CELLS (2018)
miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma
Rui-Min Chang et al.
CLINICAL CANCER RESEARCH (2017)
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2017)
Cancer Gene Discovery in Hepatocellular Carcinoma: The CRISPR/CAS9 Accelerator
Jean-Charles Nault
GASTROENTEROLOGY (2017)
Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice
Chun-Qing Song et al.
GASTROENTEROLOGY (2017)
ERK signalling as a regulator of cell motility
Susumu Tanimura et al.
JOURNAL OF BIOCHEMISTRY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Ursula A. Germann et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Classifier of cross talk genes predicts the prognosis of hepatocellular carcinoma
Xiaofeng Zhai et al.
MOLECULAR MEDICINE REPORTS (2017)
Long non-coding RNA CASC2 regulates cell biological behaviour through the MAPK signalling pathway in hepatocellular carcinoma
Yuanyuan Gan et al.
TUMOR BIOLOGY (2017)
Long non-coding RNA Igf2as controls hepatocellular carcinoma progression through the ERK/MAPK signaling pathway
Han Bao et al.
ONCOLOGY LETTERS (2017)
Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells
Jing Li et al.
ONCOLOGY LETTERS (2017)
BANCR: a novel oncogenic long non-coding RNA in human cancers
Yifan Zou et al.
ONCOTARGET (2017)
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia et al.
NATURE REVIEWS CANCER (2017)
MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma
Kun Zhou et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Hepatitis B Virus Core Antigen Stimulates IL-6 Expression via p38, ERK and NF-κB Pathways in Hepatocytes
Yang-Xia Li et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Cabozantinib: Mechanism of action, efficacy and indications
Valerie Cochin et al.
BULLETIN DU CANCER (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy
Hye-Lim Ju et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Increased expression of LncRNA BANCR and its prognostic significance in human hepatocellular carcinoma (Publication with Expression of Concern. See vol. 17, 2019)
Tao Zhou et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2016)
Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
Zeynep Firtina Karagonlar et al.
CANCER SCIENCE (2016)
Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53
Wen-Ting Liu et al.
CELL CYCLE (2016)
Negative feedback regulation of the ERK1/2 MAPK pathway
David Lake et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma
T. Vescovo et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant -catenin
Junyan Tao et al.
HEPATOLOGY (2016)
Mechanisms of HBV-induced hepatocellular carcinoma
Massimo Levrero et al.
JOURNAL OF HEPATOLOGY (2016)
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Eva Dombi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)
Andrew M. Kidger et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
Lei Li et al.
ONCOLOGY LETTERS (2016)
Ras activation revisited: role of GEF and GAP systems
Anne Hennig et al.
BIOLOGICAL CHEMISTRY (2015)
Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model
Youya Nakazawa et al.
CANCER SCIENCE (2015)
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
Benedicte Delire et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2015)
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
Kornelius Schulze et al.
NATURE GENETICS (2015)
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Luping Lin et al.
NATURE GENETICS (2015)
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
High-throughput functional genomics using CRISPR-Cas9
Ophir Shalem et al.
NATURE REVIEWS GENETICS (2015)
Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies
Varsha P. Brahmkhatri et al.
BIOMED RESEARCH INTERNATIONAL (2015)
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Christopher J. Caunt et al.
NATURE REVIEWS CANCER (2015)
Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy
Chuan Chen et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma
Wei-Tien Tai et al.
CLINICAL CANCER RESEARCH (2014)
Fibroblast Growth Factor Signaling in Liver Carcinogenesis
Dalbir S. Sandhu et al.
HEPATOLOGY (2014)
Long Non-coding RNA URHC Regulates Cell Proliferation and Apoptosis via ZAK through the ERK/MAPK Signaling Pathway in Hepatocellular Carcinoma
Wei-Hua Xu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2014)
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
Mohammad Hojjat-Farsangi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice
H. Ye et al.
ONCOGENE (2014)
MEK in cancer and cancer therapy
Cindy Neuzillet et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Targeting the insulin-like growth factor pathway in hepatocellular carcinoma
Monica Enguita-German et al.
WORLD JOURNAL OF HEPATOLOGY (2014)
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Yuji Yamamoto et al.
VASCULAR CELL (2014)
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
Jordi Bruix et al.
EUROPEAN JOURNAL OF CANCER (2013)
Epidemiology of Hepatocellular Carcinoma Consider the Population
Sahil Mittal et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
Investigation of Oncogenic Cooperation in Simple Liver-Specific Transgenic Mouse Models Using Noninvasive In Vivo Imaging
Hye-Lim Ju et al.
PLOS ONE (2013)
A rare point mutation in the Ras oncogene in hepatocellular carcinoma
Akinobu Taketomi et al.
SURGERY TODAY (2013)
AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways
Coral Ho et al.
HEPATOLOGY (2012)
Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways
Chunmei Wang et al.
JOURNAL OF HEPATOLOGY (2012)
Differential expression of sprouty genes in hepatocellular carcinoma
Yongyut Sirivatanauksorn et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma
L. Chen et al.
EJSO (2011)
Increased Lipogenesis, Induced by AKT-mTORC1-RPS6 Signaling, Promotes Development of Human Hepatocellular Carcinoma
Diego F. Calvisi et al.
GASTROENTEROLOGY (2011)
Modeling Hepatitis B Virus X-Induced Hepatocellular Carcinoma in Mice With the Sleeping Beauty Transposon System
Vincent W. Keng et al.
HEPATOLOGY (2011)
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer
Diego F. Calvisi et al.
JOURNAL OF HEPATOLOGY (2011)
Raf kinases in cancer-roles and therapeutic opportunities
G. Maurer et al.
ONCOGENE (2011)
Non-ATP Competitive Protein Kinase Inhibitors
L. Garuti et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Synergistic Role of Sprouty2 Inactivation and c-Met Up-Regulation in Mouse and Human Hepatocarcinogenesis
Susie A. Lee et al.
HEPATOLOGY (2010)
Cancer gene discovery in hepatocellular carcinoma
Lars Zender et al.
JOURNAL OF HEPATOLOGY (2010)
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Dominico Vigil et al.
NATURE REVIEWS CANCER (2010)
Robe of Cyclin D1 as a Mediator of c-Met- and beta-Catenin-Induced Hepatocarcinogenesis
Mohini A. Patil et al.
CANCER RESEARCH (2009)
Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and MAPK/ERK activation
J. -L. Qu et al.
DIGESTIVE AND LIVER DISEASE (2009)
Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis
Chuan-Rui Xu et al.
MOLECULAR CANCER RESEARCH (2009)
Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma
Diego F. Calvisi et al.
CANCER RESEARCH (2008)
Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer
Susie A. Lee et al.
HEPATOLOGY (2008)
Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma
Guo-Hua Qiu et al.
JOURNAL OF HEPATOLOGY (2007)
Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors
T. Yoshida et al.
ONCOGENE (2006)
Loss of raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells
Han Chu Lee et al.
GASTROENTEROLOGY (2006)
Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse
CM Carlson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer
PA Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours
J Borlak et al.
ONCOGENE (2005)
Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma
JS Campbell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Liver-targeted disruption of Apc in mice activates β-catenin signaling and leads to hepatocellular carcinomas
S Colnot et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Hepatocarcinogenesis in mice with beta-catenin and Ha-Ras gene mutations
N Harada et al.
CANCER RESEARCH (2004)
Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine
N Horiguchi et al.
ONCOGENE (2002)
Spred is a Sprouty-related suppressor of Ras signalling
T Wakioka et al.
NATURE (2001)
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice
R Wang et al.
JOURNAL OF CELL BIOLOGY (2001)
Expression of hepatocyte growth factor in human hepatocellular carcinoma
J Guirouilh et al.
JOURNAL OF HEPATOLOGY (2001)
Hepatitis C virus core protein activates the MAP/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor α
J Hayashi et al.
HEPATOLOGY (2000)
Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the Raf kinase inhibitor protein
K Yeung et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
